1
Katalin Kariko, Drew Weissman: RNA containing modified nucleosides and methods of use thereof. The Trustees of the University of Pennsylvania, Riverside Law, September 16, 2014: US08835108 (42 worldwide citation)

This invention provides RNA, oligoribonucleotide, and polyribonucleotide molecules comprising pseudouridine or a modified nucleoside, gene therapy vectors comprising same, methods of synthesizing same, and methods for gene replacement, gene therapy, gene transcription silencing, and the delivery of ...


2
Antonin de Fougerolles, Kristy M Wood, Sayda M Elbashir, Jason P Schrum: Modified polynucleotides for the production of G-CSF. Moderna Therapeutics, DT Ward P C, Donna T Ward, Jennifer F Bryan, March 25, 2014: US08680069 (38 worldwide citation)

The present disclosure provides, inter alia, formulation compositions comprising modified nucleic acid molecules which may encode a protein, a protein precursor, or a partially or fully processed form of the protein or a protein precursor. The formulation composition may further include a modified n ...


3
KRAMPS THOMAS DR, PROBST JOCHEN DR, VOSS SOEHNKE DR, HOERR INGMAR DR: Acides nucléiques de formule (NuGIXmGnNv)a et dérivés associés en tant que agent/adjuvant de stimulation immunitaire, Nukleinsäure der Formel (NuGIXmGnNv)a und Derivate davon als immunstimulierendes Mittel/Adjuvans, Nucleic acids comprising formula (NuGIXmGnNv)a and derivatives thereof as an immunostimulating agents/adjuvant. CUREVAC, January 23, 2013: EP2548960-A1 (37 worldwide citation)

The present invention relates to nucleic acids of the general formula (I): (N u G l X m G n N v ) a and derivatives thereof as an immunostimulating agent/adjuvant and to compositions containing same, optionally comprising an additional adjuvant. The present invention furthermore relates to a pharmac ...


4
EHRICH MATHIAS: Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non invasive prenatal diagnoses. Sequenom, Tam Tobey M, March 24, 2011: WO/2011/034631 (16 worldwide citation)

Provided are compositions and processes that utilize genomic regions that are differentially methylated between a mother and her fetus to separate, isolate or enrich fetal nucleic acid from a maternal sample. The compositions and processes described herein are particularly useful for non-invasive pr ...


5
Katalin Kariko, Drew Weissman, Gary Dahl, Anthony Person, Judith Meis, Jerome Jendrisak: RNA preparations comprising purified modified RNA for reprogramming cells. The Trustees of the University of Pennsylvania, Casimir Jones S C, April 21, 2015: US09012219 (9 worldwide citation)

The present invention provides compositions and methods for reprogramming somatic cells using purified RNA preparations comprising single-strand mRNA encoding an iPS cell induction factor. The purified RNA preparations are preferably substantially free of RNA contaminant molecules that: i) would act ...


6
Antonin de Fougerolles, Sayda M Elbashir: Split dose administration. MODERNA THERAPEUTICS, DT WARD PC, Donna T Ward, Jennifer F Bryan, November 17, 2015: US09186372 (8 worldwide citation)

The present disclosure provides, inter alia, formulation compositions comprising modified nucleic acid molecules which may encode a protein, a protein precursor, or a partially or fully processed form of the protein or a protein precursor. The formulation composition may further include a modified n ...


7
Antonin de Fougerolles, Kristy M Wood, Pedro Valencia: Formulation and delivery of PLGA microspheres. Moderna Therapeutics, DT Ward PC, Donna T Ward, Jennifer F Bryan, March 29, 2016: US09295689 (7 worldwide citation)

The present disclosure provides, inter alia, formulation compositions comprising modified nucleic acid molecules which may encode a protein, a protein precursor, or a partially or fully processed form of the protein or a protein precursor. The formulation composition may further include a modified n ...


8
KARIKO KATALIN, WEISSMAN DREW: [fr] ARN contenant des nucléosides modifiées et leurs procédés dutilisation, [de] Modifizierte nukleosidhaltige RNA und Verwendungsverfahren dafür, [en] RNA containing modified nucleosides and methods of use thereof. UNIV PENNSYLVANIA, April 10, 2013: EP2578685-A2 (7 worldwide citation)

[en] This invention provides RNA, oligoribonucleotide, and polyribonucleotide molecules comprising pseudouridine or a modified nucleoside, gene therapy vectors comprising same, methods of synthesizing same, and methods for gene replacement, gene therapy, gene transcription silencing, and the deliver ...


9
HARTMANN GUNTHER PROF DR, SCHLEE MARTIN DR RER NAT: Oligonucléotide de triphosphate 5 avec extrémité franche et utilisations associées, 5-Triphosphat-Oligonukleotid mit stumpfem Ende, und dessen Verwendungen, 5Triphosphate oligonucleotide with blunt end and uses thereof. HARTMANN GUNTHER, October 31, 2012: EP2518150-A2 (7 worldwide citation)

The present invention provides an oligonucleotide which is capable of activating RIG-I and inducing an anti-viral, in particular, an IFN, response in cells expressing RIG-I. The oligonucleotide of the present invention has a double-stranded section of at least 21 bp, at least one 5' triphosphate, an ...


10
HARTMANN GUNTHER, SCHLEE MARTIN: [fr] Oligonucléotide à 5-triphosphate présentant une extrémité franche et ses utilisations, [de] 5-Triphosphat-Oligonukleotid mit stumpfem Ende und dessen Verwendung, [en] 5 triphosphate oligonucleotide with blunt end and uses thereof. HARTMANN GUNTHER, November 25, 2009: EP2123757-A1 (7 worldwide citation)

[en] The present invention provides an oligonucleotide which is capable of activating RIG-I and inducing an anti-viral, in particular, an IFN, response in cells expressing RIG-I. The oligonucleotide of the present invention has a double-stranded section of at least 21bp, at least one 5' triphosphate ...